#38 Hailey Gilmore: The Complexity of Psychedelic Science - Why MDMA therapy rollout depends on regulation, trial design, and real-world logistics

MDMA-assisted therapy development is slowed less by science than by implementation complexity, and Hailey Gilmore breaks down the moving parts needed to bring it to market. The conversation focuses on regulatory and operational hurdles, including FDA approval pathways, DEA licensing, state-by-state legislative and compliance differences, and the practical interplay between insurance, healthcare institutions, and drug rescheduling. It also covers why establishing investigator-initiated trial programs and protocols requires navigation across multiple research and regulatory stakeholders. Gilmore draws parallels to HIV prevention and the rollout of PrEP to explain adoption barriers for psychedelics, emphasizing clinician training and insurance buy-in. She also compares smaller, flexible clinics with large academic centers, arguing that smaller sites may move faster to deliver treatment, while bigger institutions can face slower execution. The episode ends by considering how potential federal health policy shifts could affect momentum for psychedelic public health implementation.